MaxCyte
IPOBest-in-Class Electroporation Systems
MaxCyte was founded in 1999, is headquartered in Gaithersburg, United States, and lists 51–200 employees.
- Headquarters
- Gaithersburg, Maryland
- Employees
- 51–200
- Founded
- 1999
- Business Model
- B2B
- Website
- maxcyte.com
- Type
- Public
About
MaxCyte's ExPERT platform is built on the company's proven, non-viral Flow Electroporation technology, designed to enable transfection with high efficiency at any scale, from discovery through GMP biomanufacturing. Built for flexibility and precision, the platform empowers researchers to engineer complex cells with confidence. MaxCyte's partnership-driven licensing model provides more than access to leading non-viral transfection technology, it offers a strategic pathway to clinic and commercialization through flexible licensing, expert support, and proven scalability, helping partners accelerate development while mitigating risk.
Summary
MaxCyte is a Biotech company based in Gaithersburg, United States, founded in 1999. It lists 51–200 employees.
Tech & App Stack
4 technologies & apps tracked
Every product and vendor across these categories, with where each signal came from.
Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.
Exit History
Aug 2021
Similar Companies
Altos Labs combines academic science and industry development to create medicines that restore ce...
BridgeBio develops treatments for genetic conditions through autonomous condition-focused teams s...
AI-first drug discovery company using AlphaFold-derived models to design therapeutics and acceler...
Asymchem is a pharmaceutical CDMO providing R&D, chemistry, manufacturing, and control services t...
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/maxcyte"><img src="https://indexed.vc/api/badge/company/maxcyte" alt="MaxCyte on Indexed.vc" width="260" height="76" /></a>